JP5997162B2 - アプレピタントl−プロリン組成物および共結晶 - Google Patents
アプレピタントl−プロリン組成物および共結晶 Download PDFInfo
- Publication number
- JP5997162B2 JP5997162B2 JP2013529758A JP2013529758A JP5997162B2 JP 5997162 B2 JP5997162 B2 JP 5997162B2 JP 2013529758 A JP2013529758 A JP 2013529758A JP 2013529758 A JP2013529758 A JP 2013529758A JP 5997162 B2 JP5997162 B2 JP 5997162B2
- Authority
- JP
- Japan
- Prior art keywords
- aprepitant
- crystal
- proline
- disease
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Description
優先権の主張を2010年9月23日に出願された米国出願特許番号61/385,744号、2011年2月4日に出願された米国出願特許番号第61/439,654号、および2011年6月17日に出願された米国出願特許番号第61/498,214号に対して優先権を主張し、これらを参照することにより本書に援用する。
本発明は、新規アプレピタント組成物およびアプレピタントを含有する共結晶化合物に関し、より詳しくは、本発明はアプレピタントL−プロリン組成物、アプレピタントL−プロリン共結晶、アプレピタントL−プロリンまたはアプレピタントL−プロリン共結晶の治療上の使用、およびアプレピタント共結晶を含有する医薬品に関する。
サブスタンスP(ニューロキニン−1:NK−1)の神経ペプチド受容体は、哺乳動物の神経系、循環系、および末梢組織の全体に分布しており、嗅覚、視覚、疼痛、血管拡張、胃運動、および運動調節の知覚を含む多くの生物学的プロセスの調節に関与する。サブスタンスPアンタゴニストは、神経精神病、炎症性疾患、疼痛(片頭痛を含む)、皮膚疾患、喘息および他の呼吸器疾患、ならびに嘔吐に対するその実用性に関して研究されている。サブスタンスPは、掻痒としても一般に知られている掻痒症の主要伝達物質であることが知られている。サブスタンスPアンタゴニストとしてのアプレピタントには、掻痒症の処置で治療効果があることが研究から分かっている(S.Staender. "Targeting the neurokinin Receptor 1 with aprepitant: a novel antipruritic strategy" PLoS One. 2010; 5(6) e10968)。掻痒または皮膚炎の種類として、限定されるものではないが、以下のものが挙げられる。すなわち、a)乾癬性掻痒症、血液透析に起因する掻痒、水因性掻痒症、および皮膚障害(例えば、接触皮膚炎)、全身性障害、ニューロパシー、心因性またはそれらの組み合わせが原因のかゆみ;b)アレルギー反応、虫刺され、過敏症(例えば、皮膚乾燥、にきび、湿疹、乾癬)、炎症状態または怪我が原因の掻痒;c)外陰部前庭炎に関連する掻痒;ならびにd)別の治療薬(例えば、抗生物質、抗ウイルス薬および抗ヒスタミン剤)の投与による皮膚炎または炎症性作用である。
EMEND(登録商標)処方情報
Claims (9)
- 1:1:1アプレピタントL−プロリンH2O共結晶。
- 以下の少なくとも1つを特徴とする1:1:1アプレピタントL−プロリンH2O共結晶:
6.4、9.4、11.9、12.9、14.6、および18.8(°2θ±0.2°2θ)から選択される少なくとも3つのピークを有する粉末X線回折パターン;
図1
により示される粉末X線回折パターン;
294Kの温度でのP212121空間群;または
294Kの温度でのa=9.1963(4)Å、b=12.8332(9)Å、c=27.4289(19)Å、α=90°、β=90°、およびγ=90°の単位格子寸法。 - 請求項1または2の1:1:1アプレピタントL−プロリンH2O共結晶および薬学的に許容される担体を含む医薬組成物。
- 治療有効量の請求項1または2の1:1:1アプレピタントL−プロリンH2O共結晶を含む、嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための医薬。
- 嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための請求項3の医薬組成物。
- 1:1:1アプレピタントL−プロリン水和物。
- 請求項6の1:1:1アプレピタントL−プロリン水和物および薬学的に許容される担体を含む医薬組成物。
- 治療有効量の請求項6の1:1:1アプレピタントL−プロリン水和物を含む、嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための医薬。
- 嘔吐に関連する傷害、神経精神病、炎症性疾患、疼痛、癌、皮膚疾患、掻痒、呼吸器疾患、または中毒を処置または予防するための請求項7の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38574410P | 2010-09-23 | 2010-09-23 | |
US61/385,744 | 2010-09-23 | ||
US201161439654P | 2011-02-04 | 2011-02-04 | |
US61/439,654 | 2011-02-04 | ||
US201161498214P | 2011-06-17 | 2011-06-17 | |
US61/498,214 | 2011-06-17 | ||
PCT/IB2011/054210 WO2012038937A1 (en) | 2010-09-23 | 2011-09-23 | Aprepitant l-proline composition and cocrystal |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013537901A JP2013537901A (ja) | 2013-10-07 |
JP2013537901A5 JP2013537901A5 (ja) | 2016-02-12 |
JP5997162B2 true JP5997162B2 (ja) | 2016-09-28 |
Family
ID=44907915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529758A Active JP5997162B2 (ja) | 2010-09-23 | 2011-09-23 | アプレピタントl−プロリン組成物および共結晶 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9029369B2 (ja) |
EP (1) | EP2618828B1 (ja) |
JP (1) | JP5997162B2 (ja) |
KR (1) | KR101833578B1 (ja) |
CN (1) | CN103221049B (ja) |
AR (1) | AR083095A1 (ja) |
AU (1) | AU2011306391B2 (ja) |
BR (1) | BR112013006651A2 (ja) |
CA (1) | CA2846460C (ja) |
ES (1) | ES2616752T3 (ja) |
HK (1) | HK1187554A1 (ja) |
IL (1) | IL225443A0 (ja) |
TW (1) | TWI540131B (ja) |
WO (1) | WO2012038937A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013006651A2 (pt) | 2010-09-23 | 2017-07-18 | Nuformix Ltd | composição e cocristal de aprepitante l-prolina |
JP6178799B2 (ja) * | 2011-11-25 | 2017-08-09 | ナフォーミックス リミテッド | アプレピタントl−プロリン溶媒和化合物−組成物及び共結晶 |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
US20160324881A1 (en) * | 2013-12-30 | 2016-11-10 | Oncoprevent Gmbh | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer |
BR112020016205A2 (pt) | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
US20050025791A1 (en) | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
EP1608339B8 (en) * | 2003-02-28 | 2012-04-25 | McNeill-PPC, Inc. | Pharmaceutical co-crystal of celecoxib-nicotinamide |
EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
WO2009108828A2 (en) * | 2008-02-27 | 2009-09-03 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
BR112013006651A2 (pt) | 2010-09-23 | 2017-07-18 | Nuformix Ltd | composição e cocristal de aprepitante l-prolina |
-
2011
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en active Application Filing
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active IP Right Grant
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
-
2014
- 2014-01-23 HK HK14100748.9A patent/HK1187554A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TWI540131B (zh) | 2016-07-01 |
KR20140040671A (ko) | 2014-04-03 |
US20130252949A1 (en) | 2013-09-26 |
JP2013537901A (ja) | 2013-10-07 |
CN103221049B (zh) | 2015-11-25 |
EP2618828A1 (en) | 2013-07-31 |
BR112013006651A2 (pt) | 2017-07-18 |
WO2012038937A1 (en) | 2012-03-29 |
CN103221049A (zh) | 2013-07-24 |
IL225443A0 (en) | 2013-06-27 |
HK1187554A1 (zh) | 2014-04-11 |
AR083095A1 (es) | 2013-01-30 |
ES2616752T3 (es) | 2017-06-14 |
US9029369B2 (en) | 2015-05-12 |
KR101833578B1 (ko) | 2018-02-28 |
EP2618828B1 (en) | 2016-11-23 |
CA2846460A1 (en) | 2012-03-29 |
AU2011306391B2 (en) | 2016-12-15 |
AU2011306391A1 (en) | 2013-04-11 |
CA2846460C (en) | 2019-01-08 |
TW201217366A (en) | 2012-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5997162B2 (ja) | アプレピタントl−プロリン組成物および共結晶 | |
US8779146B2 (en) | Cilostazol cocrystals and compositions | |
CN112236413A (zh) | 结晶曲尼司特盐及其药物用途 | |
JP6178799B2 (ja) | アプレピタントl−プロリン溶媒和化合物−組成物及び共結晶 | |
US20210094961A1 (en) | Form of ponatinib | |
JP2023538455A (ja) | オラパリブシュウ酸共結晶及びその医薬的使用 | |
US8871793B2 (en) | Metaxalone cocrystals | |
AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
US11891401B2 (en) | Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide | |
JP2024517608A (ja) | 結晶性カルバゾール誘導体 | |
TW202214645A (zh) | 含氮雜環化合物的鹽及其鹽的固體形式、藥物組合物和用途 | |
WO2018187643A1 (en) | Novel forms of afatinib dimaleate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140919 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151120 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20151218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160715 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160809 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160825 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5997162 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |